Title:

Early and long-term risk of new-onset atrial fibrillation after transient ischemic attack

Running head:

Atrial fibrillation after TIA

Authors:

Francisco Purroy MD PhD^{1,2,*}, Mikel Vicente-Pascual MD^{1,2}, Gloria Arque PhD², Mariona Baraldes-Rovira MD¹, Robert Begue MD², Joan Farre² MD, Yhovany Gallego MD¹, M. Pilar Gil-Villar MD^{1,2}, Gerard Mauri MD PhD^{1,2}, Nuria Montalà MD^{2,3}, Miriam Paul-Arias MD^{1,2}, Cristina Pereira Ms², Coral Torres-Querol Ms², Daniel Vazquez-Justes MD^{1,2}.

Affiliations:

1 Stroke Unit, Department of Neurology, Hospital Universitari Arnau de Vilanova de Lleida, Lleida (Spain).

2 Clinical Neurosciences Group, Institut de Recerca Biomèdica de Lleida (IRBLleida), Universitat de Lleida, Lleida, (Spain).

3 Hospital Universitari Santa Maria de Lleida, Lleida (Spain)

The authors declare no conflicts of interest

*** Corresponding author:** Francisco Purroy, MD, PhD. Stroke Unit. Department of Neurology. Professor of the Universitat de Lleida. IRBLleida. Hospital Universitari Arnau

de Vilanova de Lleida. Avda Rovira Roure, 80. Lleida 25198, Spain.

fpurroygarcia@gmail.com Phone: 973705200/Fax 973248754

Word count: 6240

Tables: 3

Figures 3

Keywords: transient ischemic attack; acute ischemic stroke; prognosis; atrial
fibrillation; biomarkers; NT-ProBNP; etiology; vascular risk factors

Abstract:

Background: Transient ischemic attack (TIA) provides a unique opportunity to optimize secondary preventive treatments to avoid subsequent ischemic stroke (IS). Although atrial fibrillation (AF) is the leading cause of cardioembolism in IS and anticoagulation prevents stroke recurrence (SR), limited data exists about the risk of new-onset AF after TIA.

Methods: We carried out a prospective cohort study of consecutive patients with TIA from January 2006 to June 2010. The risk of new diagnosis of AF and SR was defined after a median follow-up time of 6.5 (5.0-9.6) years. In a subgroup of consecutive patients, a panel of biomarkers was assessed during the first 24 h of the onset of symptoms.

Results: 723 TIA patients were included. New-onset AF was diagnosed in 116 (16.0%) patients, 42 (36.2%) of them during admission. 204 (28.2%) patients were included in the biomarker substudy. New-onset AF was associated with sex (female) (hazard ratio [HR] 1.61 [95% CI, 1.07- 2.41]), age (HR 1.05 [95% CI, 1.03-1.07]), previous ischemic heart disease (HR 1.84 [95% CI 1.15-2.97]) and cortical DWI pattern (HR 2.81 [95% CI 1.87-4.21]). In the Kaplan-Meier analysis, NT-proBNP ≥ 218.2 pg/ml (log-rank test $P < 0.001$) was associated with significant risk of new-onset AF during the first five years of follow-up. Patients with a new diagnosis of AF after admission and before five years of follow-up had the highest risk of SR ($P = 0.002$).

Conclusion: The risk of new diagnosis of AF after TIA is clinically relevant. We identified clinical, neuroimaging and biomarker predictors of new-onset AF.

INTRODUCTION

Transient ischemic attack (TIA) provides a unique opportunity to optimize secondary preventive treatments and avoid subsequent ischemic stroke (IS)¹. Up to 20% of ISs are preceded by a TIA². This proportion could be significantly decreased with appropriate early management³. Although atrial fibrillation is the leading cause of cardioembolism in IS patients in both sexes^{4,5}, it is frequently unrecognized at the time of the index event⁶. Indiscriminate anticoagulation for embolic strokes of undetermined source has not proven effective in different clinical trials^{7,8}. In contrast, anticoagulation prevents stroke recurrence (SR) after IS caused by AF⁴. Therefore, the identification of AF after IS and TIA is critical⁹. A history of previous IS or TIA is a major SR risk factor in patients with AF¹⁰. Limited data exists about the risk of new-onset AF after TIA¹¹, as early management has mainly focused on the detection and treatment of intracranial or extracranial large artery atherosclerosis (LAA), which is the main predictor of SR¹²⁻¹⁴. The practice of ECG monitoring is less common for patients with TIA than for those with IS¹⁵, and when TIA patients are admitted to stroke units they are monitored for significantly shorter periods than patients with IS¹⁶. A recent meta-analysis which focused only on TIA patients evidenced a lower AF detection rate than for IS and TIA cohorts¹¹.

The aim of our study was to determine the risk of new-onset AF in a cohort of TIA patients with long-term follow-up. We describe clinical characteristics, neuroimaging features and biomarker patterns related to AF occurrence in order to identify those patients who would benefit from long-term cardiac monitoring. We also include a study of the prognostic repercussions of diagnostic delay.

METHODS

Data availability statement

Requests for access to the data reported in this article will be considered by the corresponding author.

Design and study population

The REGITELL registry (Registro de pacientes con ictus transitorio de Lleida [in Spanish]) methodology has been described in detail previously^{17,18}. Consecutive TIA patients were included from January 2006 to June 2010 following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement¹⁹. TIA was defined as a reversible episode of neurological deficit of ischemic origin that was fully resolved within 24 h.²⁰ All patients underwent standard routine diagnostic work-up which included 12-channel electrocardiography (ECG), transcranial and supra-aortic ultrasound test, head computerized tomography and laboratory tests. Clinical characteristics, previous diagnosis of AF, ABCD² score²¹ and CHA₂DS₂-VAsc risk score were recorded¹⁰. Any potential, but non-definitive, TIA events were defined by the presence of isolated, atypical symptoms such as: unsteadiness; diplopia; dysarthria; partial sensory deficit; and unusual cortical vision²². All cases were reviewed by the senior neurologist (FP) and classified by atherosclerosis and small vessel disease phenotypes according to the ASCOD classification²³. Patients in whom cardiopathy was suspected underwent extended cardiological examinations. Those patients without contraindications were evaluated by cranial MRI that included diffusion-weighted

imaging (DWI) sequences within 7 days of symptom onset. Presence of DWI abnormalities and patterns of acute ischemic lesions were also recorded^{17 24}.

New-onset AF definition and ECG procedures

AF was defined as a period of >30 seconds duration of an absolute arrhythmia without detectable P-wave activity and irregular RR interval⁴. The way AF was detected was recorded: ECG at emergency department, continuous electrocardiographic monitoring (CEM) or Holter ECG on admission, and ECG after clinical symptoms during the follow-up. Holter ECG was performed within the first 48 h after admission. Holter data were analyzed by a blinded cardiologist. CEM (GE Healthcare, Chicago, IL, USA) was started immediately after admission and maintained for three days. It included a special software for AF detection. Whenever AF was suspected, an experienced neurologist (FP, DVJ, MV or GM) reviewed the CEM report for confirmation or dismissal. When a doubt arose, the ECG was reviewed by a cardiologist. Cases of suspected abnormal baseline ECG were reviewed by the same team.

Structured clinical visits were performed by a stroke physician (FP, MBR, YG, MPGV, GM, DVJ, MVP or MP) during the follow-up period to determine the risk of further vascular events. SR was defined by the appearance of new focal symptoms or signs associated with acute ischemic changes shown in neuroimaging scans (CT or MRI) made at 7 days, 3 months, one year, five years and 10 years. If a patient moved out of the local area or if travel to the hospital was impossible, the follow-up was conducted by phone. Recurrent events and new diagnoses of AF were also actively identified by an annual review of electronic medical records¹⁸.

Biomarkers substudy

From January 2008 to June 2010, blood samples were obtained by standard venipuncture within the first 24 h after the onset of symptoms at the emergency department admission to test a panel of biomarkers²⁵ that included high-sensitivity C-reactive protein (hs-CRP), interleukin-1-alpha (IL-1 α), IL-6, tumor necrosis factor-alpha (TNF- α), neuron-specific enolase (NSE), S100b, N-terminal pro-B type natriuretic peptide (NT-proBNP), copeptin, adiponectin and neopterin. Plasma, serum and buffy coat were obtained after centrifugation at 3,000 g at 4° C for 10 min, and aliquoted into cryovials for immediate storage at -80 °C (Plataforma Biobancos PT17/0015/0027). Hs-CRP, IL-6, NSE, S100b and NT-proBNP levels were assessed in plasma samples (Hoffmann-La Roche, Basel, Switzerland) by an electrochemical chemiluminescence immunoassay using the COBAS 6000 e601 (Hoffmann-La Roche, Basel, Switzerland) at the Medical Laboratory of the HUAV. Other determinations were performed at the Clinical Neurosciences laboratory of the IRBLleida (Institut de Recerca Biomedica de Lleida). In detail, IL-1 α and TNF- α were quantified in serum using a solid-phase sandwich enzyme-linked immune sorbent assay (ELISA), commercially available in BIONOVA. The absorbance was read in a spectrophotometer using 450 nm wavelength. Copeptin was measured with a chemiluminescence sandwich immunoassay, determined with an immunoluminometric assay (Thermo Scientific B.R.A.H.M.S CT-proAVP LIA). Neopterin was quantified by competitive immunoassay using high-affinity monoclonal antibody (IBL America, MN, USA), and adiponectin was quantified with a competitive enzyme immunoassay ADIPOQ (Human) ELISA kit (Abnova).

Statistical analysis

First, we compared the baseline characteristics, ASCOD classification, presence and distribution of acute lesions in DWI, ABCD² score²¹, CHA₂DS₂-VASC¹⁰, outcomes and biomarker levels between non-AF, previous AF and new-onset AF patient groups. Second, we performed the same comparison, but excluding previous AF patients. Third, we compared previous AF and new-onset AF patients. Finally, we analyzed differences between new-onset AF groups that took into account time to diagnosis: less than one year, between one year and less than five years, and five years or more after the onset of symptoms. The quantitative variables were compared using either the student's T-test or the Mann-Whitney U test. The qualitative variables were compared using the chi-squared test or Fisher's exact test when the expected cell frequency was <5. Biomarkers were not normally distributed (P-P plot), and values were expressed as median (interquartile range). A Bonferroni correction (a multiple-comparison correction) was applied to all the significant associations to reduce the risk of finding false-positive associations. To calculate the sensitivity and specificity for biomarker cut-off values which allowed to discriminate TIA patients with new-onset AF from TIA patients without AF, a receiver operator characteristic (ROC) analysis was performed. The cumulative risks of new-onset AF after excluding patients with previous AF during follow-up were estimated using a Kaplan-Meier analysis. The results were censored at the time of the outcome event, patient death, or the end of the follow-up period. Risks were compared using the log-rank test. Data on patients with no information at 10 years were censored at the time of the last available follow-up. A Cox proportional hazards multivariable analysis was performed including clinical variables (model 1), clinical variables and neuroimaging features (model 2), clinical variables and biomarker data (model 3), and clinical variables, neuroimaging features

and biomarker data (model 4) to identify predictors of SR. It was also adjusted for patient characteristics that significantly predicted outcomes in univariate logistic regression models. We compared the risk of SR in subgroups of patients categorized according to the main identified predictors using a Kaplan-Meier analysis and the log-rank test. All the tests were 2-sided. Missing data was included as a random effect when fitting the model for multivariable analyses. The statistical analysis of the data was carried out using the SPSS statistical package, version 24.0. (SPSS, Chicago, IL, USA) and Graphpad software version 6 (LLC).

Standard protocol approvals, registrations, and patient consents

Written informed consent or assent from relatives was obtained for all the participants. The study was approved by our local Ethics Committee: the “Comité d’Ètica i Investigació Clínica de l’Hospital Universitari Arnau de Vilanova de Lleida”¹⁸.

RESULTS

723 TIA patients were included in the analysis after excluding 48 patients who were diagnosed as mimics. In 85 (11.8%) patients, AF was documented before the index event (Figure 1). New-onset AF was diagnosed in 116 (16.0%) patients: 31 (26.7%) of them after performing an ECG at the emergency room and 11 (9.5%) during admission, 18 (15.5%) after admission and during the first year of the follow-up, 29 (25.0%) between one year and five years and 27 (23.3%) beyond five years of follow-up. CEM was performed on 288 (47.4%) of the 607 patients with no previous diagnosis of AF or with no AF documented at the emergency room, and 139 (22.9%) underwent Holter ECG recording on admission. AF was identified in only 10 (3.5%) patients in CEM and no Holter ECG identified an AF event. 204 (28.2%) patients were included in the biomarker substudy. Compared to the patients not included in the substudy, a higher proportion had a previous stroke (28 [13.5%] vs. 38 [7.4%]; $P=0.010$) and events lasting from 10 to 60 minutes (84 [41.0%] vs. 164 [32.4%]; $P=0.002$) (Supplementary Table I).

Clinical and imaging characteristics of patients with new-onset atrial fibrillation

Like patients with previously diagnosed AF, patients with new-onset AF were older, had a higher proportion of carotid territory events, speech impairment and previous ischemic heart disease, but a lower proportion of non-definitive TIA events and isolated sensory impairment than patients without AF (Table 1). The proportion of women, positive DWI and cortical DWI patterns were higher in AF groups than non-AF patient groups. In addition, the CHA₂DS₂-VASc score was higher in AF groups than non-AF groups. No difference was observed in the risk of SR between groups. AF groups had significantly higher levels of NT-proBNP and adiponectin than non-AF groups.

When we compared previous and new-onset AF groups we detected a higher proportion of women in the new-onset AF group (38 [44.7%] vs. 64 [55.2%]; $P=0.095$), of previous heart failure (14 [16.5%] vs. 5 [4.3%]; $P=0.004$) and of positive DWI (28 [43.8%] versus 58 [59.8%]; $P<0.001$). Hypertension was more frequent in previous AF patients (70 [82.4%] vs. 83 [71.6%]; $P=0.095$). Finally, lesions on DWI classified as scattered in one vascular territory pattern were more frequent in the previous AF group than in the new-onset AF group (17 [60.7%] vs. 22 [37.3%]; $P=0.040$). In contrast, cortical lesion in one vascular territory was present in a greater proportion in new-onset AF patients (6 [21.4%] vs. 24 [40.7%]; $P=0.078$). Finally, previous AF patients had higher levels of NT-proBNP than new-onset AF patients (median [IQR]: 1416.0 [510.4-2507.5] vs. 466.4 [218.7-1031.0]; $P=0.009$).

When we analyzed the different categories of new-onset AF with respect to time of diagnosis from the onset of symptoms (Table 2), we identified a higher proportion of patients with cortical DWI pattern and S1 or S2 ASCOD grades in patients with new-onset AF detected ≥ 5 years after the onset of symptoms. In addition, these patients had lower levels of NT-proBNP and copeptin.

Predictors of new-onset atrial fibrillation

After the exclusion of previous AF patients, new-onset AF was associated with sex (female) (hazard ratio [HR] 1.61 [95% CI, 1.07–2.41]; $P=0.013$), age (HR 1.05 [95% CI, 1.03–1.07]; $P<0.001$), previous ischemic heart disease (HR 1.84 [95% CI 1.15-2.97]; $P=0.012$), and cortical DWI lesion pattern (HR 2.81 [95% CI 1.87-4.21]; $P<0.001$) (Table 3). A cut-off value was obtained for NT-proBNP of 218.3 pg/ml, with a sensitivity of 80.6 % and a specificity of 60.5%.

In the Kaplan-Meier analysis (Figure 2), female patients (log-rank test $P=0.002$), patients with previous ischemic heart disease (IHD) (log-rank test $P<0.001$), patients with carotid territory events (log-rank test $P=0.003$), and patients ≥ 75 years of age (log-rank test $P<0.001$) had a significantly higher risk of new-onset AF throughout follow-up. In contrast, cortical DWI lesion patterns (log-rank test $P<0.001$) and NT-proBNP ≥ 218.2 pg/ml (log-rank test $P<0.001$) were associated with a significant risk of new-onset AF during the early follow-up, specially during the first 3-5 years.

New-onset AF and risk of recurrent stroke.

Patients with a new diagnosis of AF after admission and before five years of follow-up had a higher risk of SR than patients with new-onset AF beyond five years of follow-up or during admission and than patients with previous AF or without new diagnosis of AF (log-rank test $P=0.002$) (Figure 3).

DISCUSSION

In our study of high-risk patients with TIA attended at an emergency department, we observed a nonnegligible risk of new diagnosis of AF during the long follow-up. Nearly one out of five patients without previous diagnosis of AF developed a new-onset AF. Interestingly, we identified clinical, neuroimaging and biomarker predictors of new-onset AF that could be used to indicate patients who would benefit from long-term ECG monitoring. Some of these predictors differed from clinical and neuroimaging features of previous AF patients. In addition, patients with a new diagnosis of AF beyond five years of follow-up differed in the etiological phenotype of the index event and in the pattern of biomarker levels from early diagnosis AF-groups .

Our documented risk of AF was significantly higher than the risk observed in a previous meta-analysis that included studies with a limited follow-up¹¹, but similar to the multicenter TIA registry.org project that reached five years of follow-up. Although AF-related brain ischemic events have been associated with disability strokes^{5 26}, our results suggest the need to investigate occult AF in TIA patients with suspicious embolic events. This is especially so when we take into account that delayed diagnosis is related to an increased risk of SR as correct preventive strategies are also delayed.

As in previous studies, we observed that the risk of new diagnosis of AF was related to age²⁶⁻³⁰, previous IHD³⁰ and DWI patterns³¹. We also identified sex differences in the proportion of new-onset AF. AF was more frequent among females³² as the proportion of vascular risk factors is lower than in men¹⁸. Patients with previously described predictors and high levels of NT-ProBNP in the absence of evidence of small vessel disease would clearly benefit from exhaustive ECG monitoring. The correlation between AF and high levels of this biomarker is well known among stroke and TIA

patients^{25 33}. This correlation is explained by the association between pro-BNP and atrial dilatation³³. In this regard, it should be noted that in our study patients with previous AF had higher levels of NT-proBNP than patients with new-onset AF. This should be taken into account when calculating the cut-off levels in patients with suspected cardioembolic events.

The study of cryptogenic events is a challenge. An AF episode was diagnosed during the follow-up in only one out of five patients with this condition after admission work-up. This result is in line with the failure of the RESPECT-ESUS and NAVIGATE-ESUS trials^{7 8} in demonstrating any efficacy in the prevention of SR with direct non-vitamin K agonist oral anticoagulants in patients with cryptogenic events. In these patients, arteriogenic embolism due to non-stenotic plaques or aortic arch atheroma could be the cause of the ischemic events³⁴.

Our study has some relevant limitations. First, the registry was designed with SR and not the diagnosis of new AF as the main endpoint. In this sense, ECG and echocardiographic abnormalities of atrial myopathy like left atrial enlargement or P-wave abnormalities^{35 36} were not registered. Second, a larger sample size would have better guaranteed the extrapolation of our results. Third, although there were no significant differences between patients included in the biomarker substudy and patients not included, it would have been interesting to have that information for all the patients.

In conclusion, the risk of new diagnosis of AF after TIA is clinically relevant. Old age, sex-female, previous IHD, carotid territory symptoms, cortical DWI pattern lesion, absence of evidence of small vessel disease and high levels of NT-ProBNP increase the

likelihood of new AF. Our results can be used to evaluate the benefit of long-term cardiac monitoring in selected patients.

BIBLIOGRAPHY

1. Amarenco P. Transient Ischemic Attack. *N Engl J Med* 2020;382(20):1933-41. doi: 10.1056/NEJMc1908837 [published Online First: 2020/05/14]
2. Johnston SC, Gress DR, Browner WS, et al. Short-term prognosis after emergency department diagnosis of TIA. *JAMA* 2000;284(22):2901-6.
3. Valls J, Peiro-Chamarro M, Cambray S, et al. A Current Estimation of the Early Risk of Stroke after Transient Ischemic Attack: A Systematic Review and Meta-Analysis of Recent Intervention Studies. *Cerebrovasc Dis* 2017;43(1-2):90-98. doi: 10.1159/000452978 [published Online First: 2016/12/20]
4. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). *Eur Heart J* 2020 doi: 10.1093/eurheartj/ehaa612 [published Online First: 2020/08/30]
5. Purroy F, Vena A, Forne C, et al. Age- and Sex-Specific Risk Profiles and In-Hospital Mortality in 13,932 Spanish Stroke Patients. *Cerebrovasc Dis* 2019;47(3-4):151-64. doi: 10.1159/000500205 [published Online First: 2019/05/06]
6. Haeusler KG, Tutuncu S, Schnabel RB. Detection of Atrial Fibrillation in Cryptogenic Stroke. *Curr Neurol Neurosci Rep* 2018;18(10):66. doi: 10.1007/s11910-018-0871-1 [published Online First: 2018/08/10]
7. Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. *N Engl J Med* 2018;378(23):2191-201. doi: 10.1056/NEJMoA1802686 [published Online First: 2018/05/17]
8. Diener HC, Sacco RL, Easton JD, et al. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. *N Engl J Med* 2019;380(20):1906-17. doi: 10.1056/NEJMoA1813959 [published Online First: 2019/05/16]
9. Khurshid S, Trinquart L, Weng LC, et al. Atrial Fibrillation Risk and Discrimination of Cardioembolic From Noncardioembolic Stroke. *Stroke* 2020;51(5):1396-403. doi: 10.1161/STROKEAHA.120.028837 [published Online First: 2020/04/08]
10. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 2010;137(2):263-72. doi: 10.1378/chest.09-1584 [published Online First: 2009/09/19]
11. Korompoki E, Del Giudice A, Hillmann S, et al. Cardiac monitoring for detection of atrial fibrillation after TIA: A systematic review and meta-analysis. *Int J Stroke* 2017;12(1):33-45. doi: 10.1177/1747493016669885 [published Online First: 2016/09/30]
12. Ois A, Zabalza A, Moreira A, et al. Long-term cardiovascular prognosis after transient ischemic attack: Associated predictors. *Neurology* 2018;90(7):e553-

- e58. doi: 10.1212/WNL.0000000000004965 [published Online First: 2018/01/19]
13. Amarenco P, Lavalley PC, Monteiro Tavares L, et al. Five-Year Risk of Stroke after TIA or Minor Ischemic Stroke. *N Engl J Med* 2018;378(23):2182-90. doi: 10.1056/NEJMoa1802712 [published Online First: 2018/05/17]
 14. Purroy F, Jimenez Caballero PE, Gorospe A, et al. Recurrent transient ischaemic attack and early risk of stroke: data from the PROMAPA study. *J Neurol Neurosurg Psychiatry* 2013;84(6):596-603. doi: 10.1136/jnnp-2012-304005 [published Online First: 2013/01/25]
 15. Giles MF, Rothwell PM. Substantial underestimation of the need for outpatient services for TIA and minor stroke. *Age Ageing* 2007;36(6):676-80. doi: 10.1093/ageing/afm088 [published Online First: 2007/07/28]
 16. Rizos T, Quilitzsch A, Busse O, et al. Diagnostic work-up for detection of paroxysmal atrial fibrillation after acute ischemic stroke: cross-sectional survey on German stroke units. *Stroke* 2015;46(6):1693-5. doi: 10.1161/STROKEAHA.115.009374 [published Online First: 2015/05/02]
 17. Purroy F, Begue R, Gil MI, et al. Patterns of diffusion-weighted magnetic resonance imaging associated with etiology improve the accuracy of prognosis after transient ischaemic attack. *Eur J Neurol* 2011;18(1):121-8. doi: 10.1111/j.1468-1331.2010.03080.x [published Online First: 2010/05/27]
 18. Purroy F, Vicente-Pascual M, Arque G, et al. Sex-Related Differences in Clinical Features, Neuroimaging, and Long-Term Prognosis After Transient Ischemic Attack. *Stroke* 2021;52(2):424-33. doi: 10.1161/STROKEAHA.120.032814 [published Online First: 2021/01/26]
 19. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007;370(9596):1453-7. doi: 10.1016/S0140-6736(07)61602-X [published Online First: 2007/12/08]
 20. Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. *Stroke* 1990;21(4):637-76.
 21. Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. *Lancet* 2007;369(9558):283-92.
 22. Lavalley PC, Sissani L, Labreuche J, et al. Clinical Significance of Isolated Atypical Transient Symptoms in a Cohort With Transient Ischemic Attack. *Stroke* 2017;48(6):1495-500. doi: 10.1161/STROKEAHA.117.016743 [published Online First: 2017/05/11]
 23. Amarenco P, Bogousslavsky J, Caplan LR, et al. The ASCOD phenotyping of ischemic stroke (Updated ASCO Phenotyping). *Cerebrovasc Dis* 2013;36(1):1-5. doi: 10.1159/000352050 [published Online First: 2013/08/01]
 24. Purroy F, Cambray S, Mauri-Capdevila G, et al. Metabolomics Predicts Neuroimaging Characteristics of Transient Ischemic Attack Patients. *EBioMedicine* 2016;14:131-38. doi: 10.1016/j.ebiom.2016.11.010 [published Online First: 2016/11/16]
 25. Purroy F, Suarez-Luis I, Mauri-Capdevila G, et al. N-terminal pro-brain natriuretic peptide level determined at different times identifies transient ischaemic

- attack patients with atrial fibrillation. *Eur J Neurol* 2014;21(4):679-83. doi: 10.1111/ene.12222 [published Online First: 2013/06/27]
26. Buchwald F, Norrving B, Petersson J. Atrial Fibrillation in Transient Ischemic Attack Versus Ischemic Stroke: A Swedish Stroke Register (Riksstroke) Study. *Stroke* 2016;47(10):2456-61. doi: 10.1161/STROKEAHA.116.013988 [published Online First: 2016/08/27]
27. Grond M, Jauss M, Hamann G, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. *Stroke* 2013;44(12):3357-64. doi: 10.1161/STROKEAHA.113.001884 [published Online First: 2013/10/17]
28. Fernandez V, Bejot Y, Zeller M, et al. Silent atrial fibrillation after ischemic stroke or transient ischemic attack: interest of continuous ECG monitoring. *Eur Neurol* 2014;71(5-6):313-8. doi: 10.1159/000357561 [published Online First: 2014/04/02]
29. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med* 2014;370(26):2467-77. doi: 10.1056/NEJMoa1311376 [published Online First: 2014/06/26]
30. Sutarnartpong P, Dharmasaroja PA, Ratanakorn D, et al. Atrial fibrillation and paroxysmal atrial fibrillation detection in patients with acute ischemic stroke. *J Stroke Cerebrovasc Dis* 2014;23(5):1138-41. doi: 10.1016/j.jstrokecerebrovasdis.2013.09.032 [published Online First: 2013/11/06]
31. Sharobeam A, Churilov L, Parsons M, et al. Patterns of Infarction on MRI in Patients With Acute Ischemic Stroke and Cardio-Embolism: A Systematic Review and Meta-Analysis. *Front Neurol* 2020;11:606521. doi: 10.3389/fneur.2020.606521 [published Online First: 2020/12/29]
32. Cordonnier C, Sprigg N, Sandset EC, et al. Stroke in women - from evidence to inequalities. *Nat Rev Neurol* 2017;13(9):521-32. doi: 10.1038/nrneurol.2017.95 [published Online First: 2017/07/22]
33. Llombart V, Antolin-Fontes A, Bustamante A, et al. B-type natriuretic peptides help in cardioembolic stroke diagnosis: pooled data meta-analysis. *Stroke* 2015;46(5):1187-95. doi: 10.1161/STROKEAHA.114.008311 [published Online First: 2015/03/15]
34. Fuentes B, Gutierrez-Zuniga R, Diez-Tejedor E. It's Time to Say Goodbye to the ESUS Construct. *Front Neurol* 2020;11:653. doi: 10.3389/fneur.2020.00653 [published Online First: 2020/08/01]
35. Schnabel RB, Haessler KG, Healey JS, et al. Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration. *Circulation* 2019;140(22):1834-50. doi: 10.1161/CIRCULATIONAHA.119.040267 [published Online First: 2019/11/26]
36. Kamel H, Longstreth WT, Jr., Tirschwell DL, et al. The Atrial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. *Int J Stroke* 2019;14(2):207-14. doi: 10.1177/1747493018799981 [published Online First: 2018/09/11]

Sources of Funding

This study was supported by the Catalan Autonomous Government's *Agència de Gestió d'Ajuts Universitaris i de Recerca* (2017 suport a les activitats dels grups de recerca 1628) and the Instituto de Salud Carlos III, (08/1398, 11/02033 and 14/01574) and the INVICTUS plus Research Network.

Declaration of conflicting interests

The authors declare no conflicts of interest regarding research, authorship, and/or the publication of this article.

FIGURE 1 LEGEND

Figure. Proportion of patients with previous and new diagnosis of atrial fibrillation; and method of atrial fibrillation detection.

FIGURE 2 LEGEND

Figure. Kaplan-Meier event curves for the risk of new diagnosis of atrial fibrillation (AF) among patients with no previously diagnosed AF according to sex, previous ischemic heart disease (IHD), age, carotid territory event (CTE), diffusion-weighted imaging (DWI) pattern and NT-proBNP levels.

FIGURE 3 LEGEND

Figure. Kaplan-Meier event curves for the risk of stroke recurrence according to previous or new diagnosis of atrial fibrillation.

Table 1. Clinical characteristics, neuroimaging features, outcomes and biomarker level by previous and new diagnosis of atrial fibrillation.

	All	No AF	Previous AF	New diagnosis of AF	p-value comparison between all groups	p-value comparison between no previous AF and new diagnosis of AF	p-value comparison between previous AF and new diagnosis of AF
Total, n (%)	723	522 (72.2)	85 (11.8)	116 (16.0)	...	...	...
Years of follow-up, median (IQR)	6.5 (5.0-9.6)	6.6 (5.1-9.8)	5.9 (3.3-8.1)	6.7 (5.1-9.9)	0.003	0.458	0.020
Sex female, n (%)	302 (41.8)	200 (38.3)	38 (44.7)	64 (55.2)	0.003*	0.001*	0.095
Age, mean (SD) years	70.7 (11.9)	68.9 (12.4)	76.8 (8.0)	74.6 (9.9)	<0.001*	<0.001*	0.143
Previous ischemic stroke n (%)	66 (9.1)	50 (9.6)	8 (9.4)	8 (6.9)	0.660	0.363	0.515
Hypertension	481 (66.5)	328 (62.8)	70 (82.4)	83 (71.6)	0.001*	0.076	0.076
Alcoholism, n (%)	21 (2.9)	18 (3.4)	1 (1.2)	2 (1.7)	0.364	0.335	1.000
Previous ischemic heart disease, n (%)	99 (13.7)	54 (10.3)	18 (21.2)	27 (23.3)	<0.001*	<0.001*	0.724
Diabetes mellitus, n (%)	215 (29.7)	158 (30.3)	26 (30.6)	31 (26.7)	0.739	0.450	0.548
Active smoking, n (%)	102 (14.1)	86 (16.5)	3 (3.5)	13 (11.2)	0.004	0.156	0.047
Previous peripheral artery disease, n (%)	26 (3.6)	24 (4.6)	0 (0)	2 (1.7)	0.054	0.157	0.224
Hypercholesterolemia, n (%)	246 (34.0)	170 (32.6)	31 (36.5)	45 (38.8)	0.388	0.199	0.737
Previous heart failure, n (%)	31 (4.3)	12 (2.3)	14 (16.5)	5 (4.3)	<0.001*	0.224	0.004
Characteristics of the event							
Duration of the event ≥ 60', n (%)	377 (53.0)	265 (51.9)	49 (57.6)	63 (54.8)	0.065	0.525	0.300
Multiple events, n (%)	165 (22.8)	128 (24.5)	12 (14.1)	25 (21.6)	0.099	0.498	0.179
Carotid territory event, n (%)	367 (50.8)	242 (46.4)	55 (64.7)	70 (60.3)	0.001*	0.006	0.529
Vertebrobasilar event, n (%)	78 (10.8)	58 (11.1)	11 (12.9)	9 (7.8)	0.456	0.287	0.225
Undetermined territory event, n (%)	286 (39.6)	228 (43.7)	21 (24.7)	37 (31.9)	0.001*	0.020	0.266
Possible, non-definitive TIA event, n (%)	79 (10.9)	72 (13.8)	3 (3.5)	4 (3.4)	<0.001*	0.002*	0.975
Speech impairment, n (%)	449 (62.1)	302 (57.9)	62 (72.9)	85 (73.3)	0.001*	0.002*	0.958
Motor impairment, n (%)	377 (52.1)	271 (51.9)	44 (51.8)	62 (53.4)	0.954	0.765	0.813

Isolated sensory impairment, n (%)	53 (7.3)	47 (9.0)	1 (1.2)	5 (4.3)	0.015	0.095	0.197
Campimetric visual deficit, n (%)	22 (3.0)	12 (2.3)	5 (5.9)	5 (4.3)	0.141	0.225	0.613
ABCD ² score, median (IQR)	5.0 (4.0-6.0)	5.0 (4.0-6.0)	5.0 (4.0-6.0)	5.0 (4.0-6.0)	0.500	0.840	0.616
Missing	12						
CHA ₂ DS ₂ -VASC, mean (SD)	3.0 (1.6)	2.7 (1.7)	3.7 (1.3)	3.4 (1.6)	<0.001*	<0.001*	0.258
ASCOD classification, n (%)							
A1 or 2	144 (19.9)	115 (22.0)	11 (12.9)	18 (15.5)	0.065	0.118	0.608
A0 or 3	579 (80.1)	407 (78.0)	74 (87.1)	98 (84.5)			
S1 or 2	109 (15.1)	100 (19.2)	2 (2.4)	7 (6.0)	<0.001*	0.001*	0.212
S0 or 3	614 (84.9)	422 (80.8)	83 (97.6)	109 (94.0)			
Neuroimaging features							
Positive DWI, n (%)	244 (39.7)	158 (34.9)	28 (43.8)	58 (59.8)	<0.001*	<0.001*	0.046
Missing	109						
Pattern of DWI lesion, n (%)							
Scattered in one vascular territory	92 (37.6)	53 (33.5)	17 (60.7)	22 (37.3)	0.024	0.606	0.040
Cortical lesion in one vascular territory	73 (29.8)	43 (27.2)	6 (21.4)	24 (40.7)	0.082	0.056	0.078
Multiple vascular territories	19 (7.8)	12 (7.6)	2 (7.1)	5 (8.5)	0.969	0.830	0.831
Subcortical	61 (24.9)	50 (31.6)	3 (10.7)	8 (13.6)	0.004	0.007	0.709
Follow-up events							
Ischemic stroke recurrence, n (%)	98 (13.6)	65 (12.5)	12 (14.1)	21 (18.1)	0.271	0.107	0.451
Biomarker results; median (IQR)							
NSE, pg/ml	7.3 (5.0-10.0)	6.9 (4.8-9.7)	6.7 (4.9-11.0)	7.5 (5.0-10.3)	0.146	0.069	0.914
Hs-CRP, mg/l	3.6 (1.5-9.6)	3.2 (1.4-9.3)	5.2 (1.9-17.7)	2.7 (1.3-13.0)	0.228	0.970	0.182
IL-6, pg/ml	3.9 (1.8-8.5)	3.4 (1.5-7.5)	5.5 (1.9-10.1)	4.6 (2.0-7.3)	0.119	0.517	0.228
NT-proBNP, pg/ml	227.3 (76.5-561.8)	161.3 (57.2-377.9)	1416.0 (510.4-2507.5)	466.4 (218.7-1031.0)	<0.001*	<0.001*	0.009
Neopterin, nmol/l	13.4 (8.4-21.5)	12.4 (8.1-17.4)	8.6 (6.0-15.5)	11.9 (9.6-20.2)	0.493	0.550	0.254
Copeptin, pmol/l	9.8 (6.5-17.6)	8.4 (5.6-15.1)	11.7 (6.5-28.7)	9.4 (5.8-10.5)	0.260	0.288	0.405
Adiponectin, microg/ml	10.3 (7.1-14.3)	8.6 (6.0-12.9)	11.5 (8.5-18.3)	11.7 (8.2-17.8)	0.004	0.030	0.433
TNF- α , pg/ml	87.0 (63.5-144.5)	81.0 (62.3-132.8)	131.0 (55.0-147.5)	93.0 (69.0-151.0)	0.578	0.288	0.595
IL-1 α , pg/ml	98.0 (68.0-161.0)	90.5 (67.3-150.0)	146.0 (64.5-166.0)	109.0 (75.0-169.0)	0.498	0.224	0.746

S100b, pg/ml	36.9 (26.5-52.7)	34.5 (25.6-49.9)	40.9 (23.8)	31.8 (23.7-65.1)	0.541	0.963	0.299
--------------	------------------	------------------	-------------	------------------	-------	-------	-------

IQR, interquartile range; SD, standard deviation; DWI, diffusion-weighted imaging; ASCOD (A, atherosclerosis; S, small vessel disease; C, cardiac pathology; O, other causes; and D, dissection) classification. hs-CRP, high-sensitivity C-reactive protein; IL, interleukin; TNF- α , tumor necrosis factor-alpha; NSE, neuron-specific enolase; NT-proBNP, N-terminal pro-B type natriuretic peptide

* Statistical significance after Bonferroni adjustment

Table 2. Clinical characteristics, neuroimaging features, outcomes and biomarker levels in new-onset atrial fibrillation groups by time to diagnosis.

	New diagnosis of AF	New diagnosis of AF during admission	New diagnosis of AF admission <1 year	New diagnosis of AF 1-<5 years	New diagnosis of AF ≥ 5years	P value
Total, n (%)	116 (16.0)	42 (36.2)	18 (15.5)	29 (25.0)	27 (23.3)	...
Years of follow-up, median (IQR)	6.7 (5.1-9.9)					
Sex female, n (%)	64 (55.2)	21 (50.0)	10 (55.6)	16 (55.2)	17 (63.0)	0.773
Age, mean (SD) years	74.6 (9.9)	74.6 (10.4)	77.2 (11.4)	75.4 (8.7)	72.0 (9.1)	0.357
Previous ischemic stroke n (%)	8 (6.9)	4 (9.5)	0 (0)	2 (6.9)	2 (7.4)	0.616
Hypertension	83 (71.6)	29 (71.6)	14 (77.8)	20 (69.0)	20 (74.1)	0.884
Alcoholism, n (%)	2 (1.7)	0 (0)	0 (0)	0 (0)	2 (7.4)	0.082
Previous ischemic heart disease, n (%)	27 (23.3)	7 (16.7)	5 (27.8)	10 (34.5)	5 (18.5)	0.306
Diabetes mellitus, n (%)	31 (26.7)	7 (16.7)	8 (44.4)	11 (37.9)	5 (18.5)	0.049
Active smoking, n (%)	13 (11.2)	3 (7.1)	2 (11.1)	2 (6.9)	6 (22.2)	0.210
Previous peripheral artery disease, n (%)	2 (1.7)	0 (0)	1 (5.6)	1 (3.4)	0 (0)	0.351
Hypercholesterolemia, n (%)	45 (38.8)	17 (40.5)	5 (27.8)	15 (51.7)	8 (29.6)	0.265
Previous heart failure, n (%)	5 (4.3)	1 (2.4)	2 (11.1)	1 (3.4)	1 (3.7)	0.480
Characteristics of the event						
Duration of the event ≥ 60', n (%)	63 (54.8)	21 (51.2)	8 (44.4)	18 (62.1)	16 (59.3)	0.582
Multiple events, n (%)	25 (21.6)	10 (23.8)	4 (22.2)	5 (17.2)	6 (22.2)	0.928
Carotid territory event, n (%)	70 (60.3)	27 (64.3)	9 (50.0)	20 (69.0)	14 (51.9)	0.425
Vertebrobasilar event, n (%)	9 (7.8)	2 (4.8)	2 (11.1)	1 (3.4)	4 (14.8)	0.328
Undetermined territory event, n (%)	37 (31.9)	7 (38.9)	8 (27.6)	8 (27.6)	9 (23.3)	0.874
Possible, non-definitive TIA event, n (%)	4 (3.4)	1 (2.4)	1 (5.6)	1 (3.4)	1 (3.7)	0.942
Speech impairment, n (%)	85 (73.3)	32 (76.2)	13 (72.2)	21 (72.4)	19 (70.4)	0.956
Motor impairment, n (%)	62 (53.4)	20 (47.6)	12 (66.7)	17 (58.6)	13 (21.0)	0.484
Isolated sensory impairment, n (%)	5 (4.3)	3 (7.1)	0 (0)	1 (3.7)	0.930	0.636

Campimetric visual deficit, n (%)	5 (4.3)	1 (2.4)	2 (11.1)	1 (3.4)	1 (3.7)	0.480
ABCD ² score, median (IQR)	5.0 (4.0-6.0)	5.0 (4.0-6.0)	5.0 (4.0-6.0)	5.0 (4.0-6.0)	5.0 (4.0-6.0)	0.414
Missing	1					
CHA ₂ DS ₂ -VASc, mean (SD)	3.4 (1.6)	3.2 (1.6)	3.8 (1.7)	3.7 (1.3)	3.1 (1.5)	0.326
ASCOD classification, n (%)						
A1 or 2	18 (15.5)	3 (7.1)	4 (22.2)	6 (20.7)	5 (18.5)	0.303
S1 or 2	7 (6.0)	0 (0)	1 (5.6)	2 (6.9)	4 (14.8)	0.093
Neuroimaging features						
Positive DWI, n (%)	58 (59.8)	22 (61.1)	9 (64.3)	12 (50.0)	15 (65.2)	0.710
Missing	19					
Pattern of DWI lesion, n (%)						
Scattered in one vascular territory	22 (37.3)	9 (39.1)	5 (55.6)	4 (33.3)	4 (26.7)	0.548
Cortical lesion in one vascular territory	24 (40.7)	11 (47.8)	2 (22.2)	6 (50.0)	5 (33.3)	0.471
Multiple vascular territories	5 (8.5)	3 (13.0)	1 (11.1)	1 (8.3)	0 (0)	0.554
Subcortical	8 (13.6)	0 (0)	1 (11.1)	1 (8.3)	6 (40.0)	0.005
Follow-up events						
Ischemic stroke recurrence, n (%)	21 (18.1)	4 (9.5)	4 (22.2)	10 (34.5)	3 (11.1)	0.038
Biomarker results; median (IQR)						
NSE, pg/ml	7.5 (5.0-10.3)	7.5 (5.0-10.2)	7.9 (5.4-10.5)	6.5 (3.7-9.4)	7.1 (4.5-9.4)	0.876
Hs-CRP, mg/l	2.7 (1.3-13.0)	3.0 (1.3-10.9)	7.3 (1.7-10.9)	4.7 (1.1-9.2)	1.7 (0.8-5.1)	0.243
IL-6, pg/ml	4.6 (2.0-7.3)	4.6 (2.6-6.3)	6.8 (1.5-12.1)	3.3 (2.8-6.4)	3.7 (1.7-12.3)	0.361
NT-proBNP, pg/ml	466.4 (218.7-1031.0)	602.7 (424.6-1885.5)	602.7 (382.8-1861.0)	614.2 (197.4-1031.0)	211.8 (202.3-263.6)	0.006
Neopterin, nmol/l	11.9 (9.6-20.2)	13.9 (9.2-19.5)	12.0 (6.0-17.9)	24.6 (10.0-39.2)	11.1 (10.3-19.6)	0.400
Copeptin, pmol/l	9.4 (5.8-10.5)	10.5 (8.0-15.6)	9.9 (9.3-10.5)	8.9 (8.3-9.4)	5.3 (3.9-7.8)	0.150
Adiponectin, microg/ml	11.7 (8.2-17.8)	11.5 (8.0-19.6)	12.0 (11.7-12.3)	12.4 (12.1-12.6)	8.9 (8.0-23.0)	0.858
TNF- α , pg/ml	93.0 (69.0-151.0)	113.0 (84.5-146.5)	71.0 (49.0-93.0)	116.5 (59.0-174.0)	94.5 (71.5-145.5)	0.587
IL-1 α , pg/ml	109.0 (75.0-169.0)	119.0 (100.5-160.0)	81.5 (57.0-106.0)	130.5 (70.0-191.0)	93.5 (69.0-152.0)	0.577
S100b, pg/ml	31.8 (23.7-65.1)	31.8 (27.2-57.1)	21.4 (16.7-26.0)	24.1 (23.7-24.6)	52.8 (36.1-81.3)	0.556

IQR, interquartile range; SD, standard deviation; DWI, diffusion-weighted imaging; ASCOD (A, atherosclerosis; S, small vessel disease; C, cardiac pathology; O, other causes; and D, dissection) classification. hs-CRP, high-sensitivity C-reactive protein; IL, interleukin; TNF- α , tumor necrosis factor-alpha; NSE, neuron-specific enolase; NT-proBNP, N-terminal pro-B type natriuretic peptide

* Statistical significance after Bonferroni adjustment

Table 3. Cox proportional hazards regression model to assess risk of atrial fibrillation after TIA.

Variable	Model 1		Model 2		Model 3		Model 4	
	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Sex female	1.60 (1.10-2.31)	0.013	1.61 (1.07-2.41)	0.022	...	...	...	...
Age	1.05 (1.03-1.07)	<0.001	1.05 (1.03-1.08)	<0.001	1.07 (1.01-1.13)	0.028	1.06 (1.00-1.13)	0.042
Previous IHD	2.04 (1.32-3.16)	0.001	1.84 (1.15-2.97)	0.012	...	...	...	...
Carotid territory event	1.45 (0.98-2.14)	0.064	1.88 (1.23-2.87)	0.003	...	...	...	...
S0 or 3 ASCOD classification	2.80 (1.27-6.14)	0.010	...	...	5.19 (0.70-38.50)	0.107	5.10 (0.69-37.80)	0.111
Non-subcortical DWI pattern	...	...	2.81 (1.87-4.21)	<0.001	...	...	...	...
NT proBNP>218.2 pg/ml	...	...	...	...	4.20 (1.51-11.67)	0.006	4.10 (1.46-11.51)	0.007

DWI, diffusion-weighted imaging; HR, hazard ratio; IHD, ischemic heart disease; ASCOD (A, atherosclerosis; S, small vessel disease; C, cardiac pathology; O, other causes; and D, dissection) classification

Number of patients at risk

Female	264	223	210	195	182	168	134	102	86	69	43
Male	374	330	311	288	269	242	185	138	114	97	65

Number of patients at risk

Non previous IHD	557	491	468	437	410	372	292	217	180	151	103
Previous IHD	81	63	53	47	41	38	27	23	20	15	5

Number of patients at risk

Non CTE	326	292	279	266	252	234	196	156	133	113	77
CTE	312	262	242	217	199	176	123	84	67	53	31

Number of patients at risk

Non cortical pattern	391	357	343	325	311	285	222	161	131	110	71
Cortical pattern	159	124	113	101	95	84	62	51	44	36	28

Number of patients at risk

<65 y	190	179	173	167	162	155	121	99	89	78	52
≥65 & <75y	159	144	137	130	123	110	89	69	59	52	31
≥75y	289	231	212	186	166	145	109	72	52	36	25

Number of patients at risk

NT ProBNP <218.2 pg/ml	98	94	88	83	79	79	71	54	43	39	29
NT ProBNP ≥218.2 pg/ml	85	58	52	48	45	40	35	29	20	17	9

Non AF	522	471	451	428	405	367	281	210	175	147	135
Previous AF	85	76	67	60	52	48	38	25	20	14	12
AF during admission	42	38	36	34	30	28	23	13	10	10	10
AF within 1 year	18	15	15	10	10	7	6	4	4	3	3
AF between 1 & 5 years	29	23	21	19	17	17	12	6	6	5	4
AF beyond 5 years	27	26	25	25	25	25	23	22	19	16	15